Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $8.50.

PYXS has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Wednesday, April 10th. SVB Leerink began coverage on shares of Pyxis Oncology in a report on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 target price for the company. Leerink Partnrs reiterated an “outperform” rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. BTIG Research assumed coverage on shares of Pyxis Oncology in a report on Friday, February 9th. They set a “buy” rating and a $8.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd.

Pyxis Oncology Price Performance

PYXS opened at $4.40 on Thursday. The company has a fifty day moving average price of $5.07 and a 200-day moving average price of $3.30. The firm has a market capitalization of $259.05 million, a P/E ratio of -2.39 and a beta of 1.51. Pyxis Oncology has a one year low of $1.35 and a one year high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. On average, analysts expect that Pyxis Oncology will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $26,000. Acadian Asset Management LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $26,000. Schulhoff & Co. Inc. purchased a new stake in Pyxis Oncology in the third quarter worth approximately $44,000. Radcliffe Capital Management L.P. purchased a new stake in Pyxis Oncology in the third quarter worth approximately $106,000. Finally, Decheng Capital Management III Cayman LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $650,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.